Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective

References

• U.S. Food & Drug Administration. FDA approves drug to treat ALS. FDA News Release, May 5, 2017. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm557102.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Accessed November 27, 2017.
   Google Scholar
• Melão A. ALS Association Official Says Radicava and Swift FDA Sign-off Are Reasons for Therapy Hope. ALS News Today, 30 June 2017. Available at: www.alsnewstoday.com/2017/06/30/als-assocation-official-says-radicava-and-swift-fda-approval-are-reasons-for-therapy-hope. Accessed November 27, 2017.
   Google Scholar
• CenterWatch. Rilutek (Riluzole). Available at: http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/3/rilutek-riluzole Accessed December 12, 2017.
   Google Scholar
• Besimon G, Lacomblez L, Meininger V and the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330:581–95.
   Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. for the ALS. Riluzole Study Group II. Lancet. 1996;347:1425–31.
   PubMed Web of Science ®Google Scholar
• Abe K, Itoyama Y, Sobue G, Soji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–7.
   PubMed Web of Science ®Google Scholar
• The Edaravone (MCI-186) ALS 16 Study Group. A posthoc subgroup analysis of outcomes in the first phase 3 clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(Suppl. 1):11–9.
   Web of Science ®Google Scholar
• The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
   PubMed Web of Science ®Google Scholar
• Beauchamp TL, Childress JF. Principles of biomedical ethics. 5th ed. New York: Oxford University Press; 2001.
   Google Scholar
• Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017. [Epub ahead of print]. doi: 10.1038/nrdp.2017.71.
   Web of Science ®Google Scholar
• Al-Chalabi A, Andersen PM, Chandran S, Chio A, Corcia P, Couratier P, et al. July 2017 ENCALS statement on edaravone. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:471–4.
   PubMed Web of Science ®Google Scholar
• Nakamaru Y, Kinoshita S, Kawaguchi A, Takei K, Palumbo J, Suzuki M. Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18 (Suppl. 1):80–7.
   Web of Science ®Google Scholar
• Takei K, Tsuda K, Takahashi F, Hirai M, Palumbo J. An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotroph Lateral Scler Frontotemporal Degener.2017;18(Suppl. 1):88–97.
   Web of Science ®Google Scholar
• Konno T, Shiga A, Tsujino A, Sugai A, Kato T, Kanai K, et al. Japanese amyotrophic lateral sclerosis patients with GGGGCC hexanucleotide repeat expansion in C9ORF72. J Neurol Neurosurg Psychiatry. 2013;84:398–401.
   PubMed Web of Science ®Google Scholar
• Elman LB, Siderowf A, Houseman G, Kelley M, McCluskey LF. Venous thrombosis in an ALS population over four years. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:246–9.
   PubMed Web of Science ®Google Scholar
• Vender RL, Mauger D, Walsh S, Alam S, Simmons Z. Respiratory systems abnormalities and clinical milestones for patients with amyotrophic lateral sclerosis with emphasis upon survival. Amyotroph Lateral Scler. 2007;8:36–41.
   PubMed Web of Science ®Google Scholar
• Nielsen-Bohlman L, Panzer AM, Kindig DA, eds. Health literacy: a prescription to end confusion. Washington, DC: The National Academies Press; 2004.
   Google Scholar
• Kolva E, Rosenfeld B, Brescia R, Comfort C. Assessing decision-making capacity at end of life. Gen Hosp Psychiatry. 2014;36:392–7.
   PubMed Web of Science ®Google Scholar
• ALZFORUM: Networking for a cure. 2017. FDA approves edaravone for treatment of ALS Available at. http://www.alzforum.org/news/research-news/fda-approves-edaravone-treatment-als Accessed December 12, 2017.
   Google Scholar
• Kiebert GM, Green C, Murphy C, Mitchell JD, O’Brien M, Burrell A, et al. Patients' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis . J Neurol Sci. 2001;191:87–93.
   PubMed Web of Science ®Google Scholar
• Green C, Kiebert G, Murphy C, Mitchell JD, O’Brien M, Burrell A, et al. Patients’ health-related quality of life and health state values for motor neurone disease/amytrophic lateral sclerosis. Qual Life Res. 2003;12:565–74.
   PubMed Web of Science ®Google Scholar
• Neudert C, Wasner M, Borasio GD. Individual quality of life is not correlated with health related quality of life or physical function in patients with amyotrophic lateral sclerosis. J Palliat Med. 2004;7:551–7.
   PubMedGoogle Scholar
• Simmons Z, Bremmer BA, Robbins RA, Walsh SM, Fischer S. Quality of life in ALS depends on factors other than strength and physical function. Neurology. 2000;55:388–92.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Division of Mental Health and Prevention of Substance Abuse. WHOQOL: Measuring Quality of Life. 1997. Available at: http://www.who.int/mental_health/media/68.pdf. Accessed June 17, 2017
   Google Scholar
• Trail M, Nelson ND, Van JN, Appel SH, Lai EC. A study comparing patients with amyotrophic lateral sclerosis and their caregivers on measures of quality of life, depression, and their attitudes toward treatment options. J Neurol Sci. 2003;209:79–85.
   PubMed Web of Science ®Google Scholar
• Adelman EE, Albert SM, Rabkin JG, Del Bene ML, Tider T, O’Sullivan I. Disparities in perceptions of distress and burden in ALS patients and family caregivers. Neurology. 2004;62:1766–70.
   PubMed Web of Science ®Google Scholar
• Olsson AG, Markhede I, Strang S, Persson LI. Well-being in patients with amyotrophic lateral sclerosis and their next of kin over time. Acta Neurol Scand. 2010;121:244–50.
   PubMed Web of Science ®Google Scholar
• Lule D, Ehlich B, Lang D, Sorg S, Heimrath J, Kubler A, et al. Quality of life in fatal disease: the flawed judgement of the social environment. J Neurol. 2013;260:2836–43.
   PubMed Web of Science ®Google Scholar
• Robbins RA, Simmons Z, Bremer BA, Walsh SM, Fischer S. Quality of Life in ALS is maintained as physical function declines. Neurology. 2001;56:442–4.
   PubMed Web of Science ®Google Scholar
• Simmons Z. Patient-perceived outcomes and quality of life in ALS. Neurotherapeutics. 2015;12:394–402.
   PubMed Web of Science ®Google Scholar
• Schwartz CE, Sprangers MA. Methodological approaches for assessing response shift in longitudinal health-related quality of life research. Soc Sci Med. 1999;48:1531–48.
   PubMed Web of Science ®Google Scholar
• Carr AJ, Gibson B, Robinson PG. Measuring quality of life: is quality of life determined by expectations or experience? Br Med J. 2001;322:1240–3.
   PubMed Web of Science ®Google Scholar
• Barclay R, Tate RB. Response shift recalibration and reprioritization in health-related quality of life was identified prospectively in older men with and without stroke. J Clin Epidemiol. 2014;67:500–7.
   PubMed Web of Science ®Google Scholar
• Felgoise SH, Chakraborty BH, Bond E, Rodriguez J, Bremer BA, Walsh SM, et al. Psychological morbidity in ALS: the importance of psychological assessment beyond depression alone. Amyotroph Lateral Scler. 2010;11:351–8.
   PubMed Web of Science ®Google Scholar
• Lou JS, Reeves A, Benice T, Sexton G. Fatigue and depression are associated with poor quality of life in ALS. Neurology. 2003;60:122–3.
   PubMed Web of Science ®Google Scholar
• Korner S, Kollewe K, Abdulla S, Zapf A, Dengler R, Petri S. Interaction of physical function, quality of life, and depression for amyotrophic lateral sclerosis: characterization of a large patient cohort. BMC Neurol. 2015;15:84. Doi: 10.1186/s12883-015-0340-2.
   PubMed Web of Science ®Google Scholar
• Ganzini L, Johnston WS, Hoffman WF. Correlates of suffering in amyotrophic lateral sclerosis. Neurology. 1999;52:1434–40.
   PubMed Web of Science ®Google Scholar
• Vignola A, Guzzo A, Calvo A, Moglia C, Pessia A, Cavallo E, et al. Anxiety undermines quality of life in ALS patients and caregivers. Eur J Neurol. 2008;15:1231–6.
   PubMed Web of Science ®Google Scholar